Brand & Product Security

Podcasts

Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments. 

Embarking on the CAR-T Journey

Videos

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, details the Biosecure Act, including the ways pharma companies are preparing for it, especially from a compliance standpoint.

Pharma’s Response to the Biosecure Act

Articles

The session provides an overview of the uninsured population, and also tackles challenges faced by patients when it comes to accessing PAPs.

PAP 2025: Understanding the Uninsured Landscape

The conference’s first panel offers insight on the current state of awareness among beneficiaries of the Part D cap and Medicare Prescription Payment Plan via the PAN Foundation’s latest research.

Access USA 2025: Spreading Awareness of Medicare Part D Reforms 

The conference’s opening session highlights the sector’s current landscape of healthcare coverage and access. 

Access USA 2025: This Year’s State of the Industry

Why having these strategies for results—amid disruptions—will be critical to success. 

Building Adaptability in the Pharmaceutical Industry

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, discusses how regulatory hurdles are impacting the advancement of CGTs, along with the changes he would like to see along that front in order to accelerate patient access.

Breaking Down Regulatory Challenges in Cell Therapy Production

The 25% tax on various imports have gone into effect, resulting in retaliatory tariffs from the impacted nations. 

Tariffs on Canada and Mexico Now Official

In the fourth part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, comments on health policy developments that the pharma supply chain should be aware of.

The Connection Between Pharma Innovation and Health Policy Development

After an initial 30-day pause, the US president plans to re-enact the import taxes on the nation’s trading partners—while also doubling the 10% tariff on China. 

Legal & Regulatory